Literature DB >> 4608945

Tumor induction by murine sarcoma virus in AKR and C58 mice. Reduction of tumor regression associated with appearance of Gross leukemia virus pseudotypes.

L Chieco-Bianchi, A Colombatti, D Collavo, F Sendo, T Aoki, P J Fischinger.   

Abstract

Adult AKR and C58 mice injected intramuscularly with murine sarcoma virus, Moloney isolate (M-MSV), developed high incidence of nonregressing local tumors. Histologically, these tumors revealed the typical pleomorphism of M-MSV sarcomas; in some cases, however, neoplastic tissue showed a nodular or diffuse growth of monomorphic myoblastlike cells, reminiscent of clonal aggregates. No depression of immune reactivity was found in M-MSV-injected mice as evaluated by direct hemolytic plaque-forming cells against SRBC and by virus-neutralizing antibody production. The MSV recovered from the induced tumors proved to be, by neutralization assay, a Gross (G)-MSV pseudotype. Moreover, tumor cell suspensions absorbed out cytotoxic antibody directed against G-cell surface antigens. Therefore, the conclusion was drawn that MSV with envelope characteristics of endogenous G leukemia virus had formed in vivo through a phenotypic mixing phenomenon. The failure of tumors to regress has been interpreted as mainly due to the partial unresponsiveness of host immune reactivity towards G-MuLV specified antigens. Since MSV-tumors arose in AKR mice after a very long latent period, the possibility was considered that this relative resistance might depend on immunologic mechanisms. In fact, M-MSV-injected AKR mice immunodepressed by goat antimouse lymphocyte serum or rendered partially tolerant by neonatal M-MuLV inoculation developed sarcomas with higher incidence and with a shorter latency. Furthermore, the MSV recovered from these early tumors proved to be the original Moloney pseudotype.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4608945      PMCID: PMC2139734          DOI: 10.1084/jem.140.5.1162

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  Separation of morphological conversion and virus production in Rous sarcoma virus infection.

Authors:  H M TEMIN
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1962

2.  Influence of immune suppression on the induction of neoplasms by MLV and MSV.

Authors:  L W Law
Journal:  Bibl Haematol       Date:  1973

3.  The G (Gross) leukemia antigen.

Authors:  L J Old; E A Boyse; E Stockert
Journal:  Cancer Res       Date:  1965-07       Impact factor: 12.701

4.  Production of altered cell foci in tissue culture by defective Moloney sarcoma virus particles.

Authors:  J W Hartley; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1966-04       Impact factor: 11.205

5.  Immunosuppression by murine sarcoma virus (Moloney).

Authors:  S P Chan; W A Hook; W Turner; M A Chirigos
Journal:  Infect Immun       Date:  1970-03       Impact factor: 3.441

Review 6.  The murine sarcoma virus (MSV).

Authors:  J J Harvey; J East
Journal:  Int Rev Exp Pathol       Date:  1971

7.  Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses.

Authors:  G Geering; L J Old; E A Boyse
Journal:  J Exp Med       Date:  1966-10-01       Impact factor: 14.307

8.  Antigenic properties of murine sarcoma virus-transformed BALB-3T3 nonproducer cells.

Authors:  J R Stephenson; S A Aaronson
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

9.  Prevention of murine sarcoma virus oncogenesis in offspring of immunized female mice.

Authors:  L Chieco-Bianchi; D Collavo; G Biasi; A Colombatti
Journal:  Br J Cancer       Date:  1973-09       Impact factor: 7.640

10.  Lack of distinctive surface antigen on cells transformed by murine sarcoma virus.

Authors:  V Strouk; G Grundner; E M Fenyö; E Lamon; H Skurzak; G Klein
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  2 in total

1.  In vitro malignant progression of cells derived from Abelson murine leukaemia virus-induced thymic lymphomas.

Authors:  D Saggioro; R Zamarchi; E D'Andrea; L Chieco-Bianchi
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

2.  Immunization against primary, transplanted and spontaneous murine leukaemia using a live Moloney sarcoma virus vaccine.

Authors:  A M Mayer; M A Basombrio; C D Pasqualini
Journal:  Br J Cancer       Date:  1980-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.